Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories, as well as research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; Nanosonics AuditPro, an infection control workflow compliance management; Trophon EPR for mitigating the risk of exposure to toxic chemicals; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $2.43 | N/A |
Market Cap | $735.50M | N/A |
Shares Outstanding | 302.83M | 0.53% |
Employees | 482.00 | N/A |
Shareholder Equity | 163.86M | 18.15% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 6.49 | N/A |
P/B Ratio | 4.49 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0821 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $113.33M | N/A |
Earnings | $13.45M | N/A |
Gross Margin | 0.789 | N/A |
Operating Margin | 0.0648 | N/A |
Net income margin | 0.1187 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $148.78M | N/A |
Total Debt | $7.25M | N/A |
Cash on Hand | $75.88M | N/A |
Debt to Equity | 0.2315 | -3.13% |
Cash to Debt | $10.46 | 29.65% |
Current Ratio | $5.50 | 5.99% |